Biocomposites wins two Queen’s Awards for Enterprise in Innovation and International Trade

0

Innovation Award Recognizes STIMULAN Rapid Cure as the Only Calcium Sulfate Antibiotic Carrier Approved for Use in Bone and Soft Tissue

International Trade Award Recognizes Biocomposites’ Outstanding Continued Growth in Overseas Sales

KEELE, England, April 21, 2022 /PRNewswire/ — Biocomposites, an international medical device company that designs, manufactures and markets advanced products for the management of bone and soft tissue infections, is delighted to have received two Queen’s Awards for Enterprise for Innovation and International exchange.

Biocomposites is one of only seven organizations nationwide to have won two Queen’s Awards in 2022.

The Queen’s Awards for Enterprise are one of the world’s most distinguished business awards, celebrating and recognizing entrepreneurial excellence in British business. Announced annually by Her Majesty The Queen, the awards follow a rigorous and highly competitive judging process and are only awarded to organizations that maintain the highest standards of business excellence.

Established in Staffordshire in 1997, Biocomposites now employs more than 200 people and specializes in the development of innovative calcium compounds for surgical use, targeting the risks of infection in the fields of musculoskeletal infection, orthopedics, traumatology, spine, foot and ankle and podiatry.

Biocomposites was recognized in the Innovation category for the innovative development of STIMULAN® Rapid Cure, the first and only calcium sulfate-based antibiotic carrier approved for use in infected bone and soft tissue. STIMULAN was developed to meet the growing need to reduce infection rates during surgical procedures.

Biocomposites was also recognized in the International Trade category for its continued outstanding growth in overseas sales. Over the past six years, sales have increased more than 200% with sales of its products in 40 countries, including United States, the Netherlands, China, Canada and India.

Michael HarrisManaging Director of Biocomposites, said: “The Queen’s Awards are the most prestigious business awards in the UK and we are proud that Biocomposites has been honored with two of them. It is great to see our relentless focus on research and development recognized with an award. innovation for STIMULAN as well as recognition for our incredible growth in global markets I would like to thank the entire team at Biocomposites whose dedication to innovation and helping patients has made this achievement possible.

About biocomposites

Biocomposites is an international medical device company that designs, manufactures and markets world-leading products for the management of infections in bone and soft tissue. Based in Keele, UK, it operates globally through Europe, UNITED STATES, Canada, China and India. Biocomposites is a world leader in the development of innovative calcium compounds for surgical use. Its products regenerate bone and target a wide range of infection risks in various specialties, including musculoskeletal infections, orthopedics, trauma, spine, foot and ankle, and podiatry. Biocomposite products are now used in over 120,000 procedures per year and sold in over 40 countries worldwide. Please visit biocomposites.com to learn more.

About STIMULAN

STIMULAN is the only calcium sulphate antibiotic carrier approved in the EU for use in bone and soft tissue. It can be mixed with antibiotics: vancomycin, gentamicin and tobramycin and allows surgeons to target high concentrations of antibiotics at the point of infection at levels that are systemically unattainable – reducing infection rate, reducing costs and improve patient outcomes. In Canada, STIMULAN can be used to treat bacterial infections in the soft tissues surrounding bone, making it the only calcium matrix approved to treat bacterial infections. In the UNITED STATESSTIMULAN is allowed to be used on infected sites.

SOURCE Biocomposites

Share.

Comments are closed.